Focus: ICU Medical manufactures disposable medical products for critical care settings, with a focus on cardiovascular and infusion therapies delivered through single-use containers and systems. The company operates from San Clemente, CA with a lean, specialized footprint in the medical device/biotech space.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Growing — net +14 jobs in 30d
59 jobs added vs 45 removed. Steady team buildout.
ICU Medical offers operational stability in a niche market but carries significant patent cliff risk and limited innovation upside—suitable for manufacturing/supply chain professionals seeking process-focused roles, but risky for those betting on pipeline growth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core legacy product with imminent exclusivity expiration; no disclosed Part D spending indicates smaller market presence than primary competitors.
Help build intelligence for ICU Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ICU Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Portfolio of IV infusion products representing bulk of current sales facing generic/biosimilar competition with no pipeline replacements identified.
Basic infusion solutions approaching LOE; containerization intellectual property likely primary differentiation as API becomes genericized.
Already past loss of exclusivity; represents shift to biosimilar/generic revenue model with compressed margins.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo